Stockreport

Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobinApproximately 80-95 percent editing was achieved i [Read more]